Ironwood to present long-term STARS trial safety data for apraglutide in SBS-IF

• Ironwood Pharmaceuticals flagged new real-world survey findings on burden of total parenteral nutrition in short bowel syndrome, scheduled for presentation at Digestive Disease Week 2026 in Chicago on May 2-5.
• Healthcare professional feedback pointed to significant treatment burden and complication risk for patients reliant on parenteral support, reinforcing demand for therapies that reduce dependence on IV nutrition or hydration.
• Separate posters will present long-term safety and tolerability findings from Ironwood’s STARS clinical trial program evaluating once-weekly apraglutide in adults with short bowel syndrome and intestinal failure.
• Additional linaclotide presentations will provide further efficacy and safety insights across constipation-related indications, including a pediatric open-label safety extension study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.